BioCryst Pharmaceuticals, Inc.
BCRX
$9.81
$0.657.10%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 1,017.50% | 191.92% | 140.12% | 100.09% | 56.59% |
| Total Depreciation and Amortization | 20.14% | 7.72% | 2.81% | 8.17% | 26.91% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 27.75% | -4.31% | 14.44% | 14.51% | -6.77% |
| Change in Net Operating Assets | 137.30% | 85.00% | 112.99% | -28.05% | -162.60% |
| Cash from Operations | 5,700.61% | 404.84% | 3,119.15% | 48.74% | 41.55% |
| Capital Expenditure | -18.81% | -2,177.97% | -15.48% | 39.15% | -21.84% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -514.16% | 68.06% | 1,377.51% | -6.05% | 166.16% |
| Cash from Investing | -569.11% | 59.88% | 1,289.34% | -5.78% | 162.50% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -55,275.84% | -10,844.96% | -18,867.66% | -32.31% | 69.44% |
| Issuance of Common Stock | -- | 27.59% | 1,142.75% | 41.61% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -597.21% | -140.61% | 52.93% | 42.51% | -41.99% |
| Cash from Financing | -5,320.54% | -4,716.48% | -3,648.02% | 150.48% | -26.73% |
| Foreign Exchange rate Adjustments | 94.48% | -154.99% | 1,050.35% | 232.65% | -349.81% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -27.26% | -120.51% | -186.13% | 102.12% | 118.13% |